Glucocorticoid use and abuse in SLE.

Area of Science:

• Rheumatology
• Pharmacology

Background:

• Glucocorticoids (GCs) are widely used for their anti-inflammatory and immunosuppressive properties.
• GCs exert effects through genomic and non-genomic pathways, with the genomic pathway linked to adverse events.
• Observational studies indicate a correlation between GC use and organ damage in Systemic Lupus Erythematosus (SLE).

Purpose of the Study:

• To review the mechanisms of action of glucocorticoids.
• To summarize the adverse effects associated with glucocorticoid therapy.
• To discuss the optimal use of glucocorticoids in managing Systemic Lupus Erythematosus.

Main Methods:

• Literature review of observational studies and clinical trials.
• Analysis of glucocorticoid mechanisms and associated adverse events.
• Evaluation of treatment strategies for Systemic Lupus Erythematosus.

Main Results:

• Glucocorticoids are associated with significant adverse effects, including osteoporosis, osteonecrosis, cataracts, hyperglycemia, cardiovascular disease, and cognitive impairment.
• The genomic pathway of GCs is implicated in many dose- and time-dependent adverse effects.
• Medium doses of GCs have shown efficacy in severe SLE, and doses below 7.5 mg of prednisone daily may minimize adverse effects.

Conclusions:

• Judicious use of GCs, including lower doses and combination therapy with hydroxychloroquine (HCQ) and other immunosuppressants, is crucial for managing SLE.
• Minimizing GC dosage is key to mitigating long-term adverse effects.
• Further clinical trials are needed to establish optimal GC dosing strategies.